QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=63DE3311F32126CEC93952F329EA64C4;jsessionid=911C3331720D630E4DA904A773AE6B34;jsessionid=2AB14533FED10E44B9CC7258465262DE;jsessionid=48A190D34B3BCE7A7610F8401F029A7C;jsessionid=B150E512BD61140F90019E9332DD4506;jsessionid=9DB6361B74E9B50690DD87C3E5C13656;jsessionid=327DA206245FCE3706F097D1D73499D4;jsessionid=A2E58A631A3B5F393BB3BB5E5BC72019 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=63DE3311F32126CEC93952F329EA64C4;jsessionid=911C3331720D630E4DA904A773AE6B34;jsessionid=2AB14533FED10E44B9CC7258465262DE;jsessionid=48A190D34B3BCE7A7610F8401F029A7C;jsessionid=B150E512BD61140F90019E9332DD4506;jsessionid=9DB6361B74E9B50690DD87C3E5C13656;jsessionid=327DA206245FCE3706F097D1D73499D4;jsessionid=A2E58A631A3B5F393BB3BB5E5BC72019